| Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS Z Yao, R Yaeger, VS Rodrik-Outmezguine, A Tao, NM Torres, MT Chang, ... Nature 548 (7666), 234-238, 2017 | 460 | 2017 |
| Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival M Drosten, A Dhawahir, EYM Sum, J Urosevic, CG Lechuga, LM Esteban, ... The EMBO journal 29 (6), 1091-1104, 2010 | 340 | 2010 |
| Targeting the MAPK pathway in KRAS-driven tumors M Drosten, M Barbacid Cancer cell 37 (4), 543-550, 2020 | 305 | 2020 |
| Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras D Matallanas, D Romano, F Al-Mulla, E O'Neill, W Al-Ali, P Crespo, ... Molecular cell 44 (6), 893-906, 2011 | 143 | 2011 |
| Allele-specific mechanisms of activation of MEK1 mutants determine their properties Y Gao, MT Chang, D McKay, N Na, B Zhou, R Yaeger, NM Torres, ... Cancer discovery 8 (5), 648-661, 2018 | 116 | 2018 |
| c-RAF ablation induces regression of advanced Kras/Trp53 mutant lung adenocarcinomas by a mechanism independent of MAPK signaling M Sanclemente, S Francoz, L Esteban-Burgos, E Bousquet-Mur, M Djurec, ... Cancer cell 33 (2), 217-228. e4, 2018 | 116 | 2018 |
| Mechanisms of disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy M Drosten, BM Pützer Nature clinical practice Oncology 3 (10), 564-574, 2006 | 103 | 2006 |
| Complete regression of advanced pancreatic ductal adenocarcinomas upon combined inhibition of EGFR and C-RAF MT Blasco, C Navas, G Martín-Serrano, O Graña-Castro, CG Lechuga, ... Cancer cell 35 (4), 573-587. e6, 2019 | 98 | 2019 |
| Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway M Drosten, EYM Sum, CG Lechuga, L Simón-Carrasco, HKC Jacob, ... Proceedings of the National Academy of Sciences 111 (42), 15155-15160, 2014 | 97 | 2014 |
| K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and function B Alvarez-Moya, C Lopez-Alcala, M Drosten, O Bachs, N Agell Oncogene 29 (44), 5911-5922, 2010 | 89 | 2010 |
| Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma M Drosten, G Hilken, M Böckmann, F Rödicker, N Mise, AN Cranston, ... Journal of the National Cancer Institute 96 (16), 1231-1239, 2004 | 86 | 2004 |
| A new mode of DNA binding distinguishes Capicua from other HMG-box factors and explains its mutation patterns in cancer M Forés, L Simón-Carrasco, L Ajuria, N Samper, S González-Crespo, ... PLoS genetics 13 (3), e1006622, 2017 | 63 | 2017 |
| Evaluation of potential mechanisms underlying genotype–phenotype correlations in multiple endocrine neoplasia type 2 N Miše, M Drosten, T Racek, A Tannapfel, BM Pützer Oncogene 25 (50), 6637-6647, 2006 | 55 | 2006 |
| The RET proto-oncogene: a potential target for molecular cancer therapy BM Pützer, M Drosten Trends in Molecular Medicine 10 (7), 351-357, 2004 | 55 | 2004 |
| The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer L Simón-Carrasco, G Jiménez, M Barbacid, M Drosten Cell Cycle 17 (6), 702-711, 2018 | 49 | 2018 |
| Inactivation of Capicua in adult mice causes T-cell lymphoblastic lymphoma L Simón-Carrasco, O Graña, M Salmón, HKC Jacob, A Gutierrez, ... Genes & Development 31 (14), 1456-1468, 2017 | 47 | 2017 |
| Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma M Böckmann, M Drosten, BM Pützer The Journal of Gene Medicine: A cross‐disciplinary journal for research on …, 2005 | 47 | 2005 |
| Antitumor Capacity of a Dominant-Negative RET Proto-Oncogene Mutant in a Medullary Thyroid Carcinoma Model M Drosten, T Stiewe, BM Pützer Human gene therapy 14 (10), 971-982, 2003 | 47 | 2003 |
| A new therapeutic approach in medullary thyroid cancer treatment: inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant M Drosten, A Frilling, T Stiewe, BM Pützer Surgery 132 (6), 991-997, 2002 | 45 | 2002 |
| Ras signaling is essential for skin development M Drosten, CG Lechuga, M Barbacid Oncogene 33 (22), 2857-2865, 2014 | 44 | 2014 |
